Have high blood pressure? Preventive medicine physician Dr. Ford Brewer knows two techniques that can lower it within minutes.

Oppenheimer adjusted its price target on Keros Therapeutics (NASDAQ:KROS) shares, reducing it significantly to $23.00 from ...

Scotiabank analyst Greg Harrison lowered the firm’s price target on Keros Therapeutics (KROS) to $41 from $44 and keeps an Outperform rating on ...

HDP affects approximately 15% of women during their reproductive years and is marked by high blood pressure during pregnancy.

BofA analyst Jason Zemansky lowered the firm’s price target on Keros Therapeutics (KROS) to $32 from $33 and keeps a Buy rating on the shares.

Elevated blood pressure is the most important risk factor for cardiovascular disease. Numerous clinical practice guidelines ...

Whether you’re a senior in high school or a senior-living resident, you’ve likely heard of Viagra (sildenafil) — the original ...

Keros Therapeutics, Inc. has announced a voluntary halt in dosing for the Tropos trial, a phase 2 clinical trial of ...

The findings suggest that specific medications may play a crucial role in preventing dementia. A study conducted by ...

Taken together with Keros’ recent pivot away from obesity, the termination of its pulmonary arterial hypertension study could ...

Shares of Keros Therapeutics (KROS) plunged nearly 20% in premarket trading on Wednesday, poised to hit an all-time low after ...

Shares in Keros Therapeutics fell sharply Wednesday morning after it said it halted trials of its treatment for pulmonary hypertension after finding adverse health effects in patients trialing the ...